Respiratory Inhaler Devices Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The respiratory inhaler devices market size has grown strongly in recent years. It will grow from $41.35 billion in 2024 to $44.33 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to smoking epidemic, allergic disorders, pharmaceutical innovation, aging population.

The respiratory inhaler devices market size is expected to see strong growth in the next few years. It will grow to $59.55 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to air quality concerns, digital health integration, regulatory emphasis on inhaler safety, personalized treatment. Major trends in the forecast period include inhaler device miniaturization, sustainability and eco-friendly inhalers, home-based care, technological advancements.

The prevalence of respiratory diseases is on the rise, and this phenomenon is poised to steer the growth of the respiratory inhaler devices market. Respiratory diseases encompass a spectrum of disorders that affect the lungs and the respiratory system, often resulting in breathing difficulties and compromised lung function. These conditions include ailments like asthma, chronic obstructive pulmonary disease (COPD), respiratory syncytial virus infection, and various other respiratory disorders. The utilization of respiratory inhaler devices is essential in delivering medications directly to the lungs, providing swift and precise relief for individuals battling respiratory illnesses. As an example, recent data from the Centers for Disease Control and Prevention, a prominent US-based public health organization, revealed an increase in tuberculosis (TB) cases reported in the United States, reaching 8,300 cases in 2022, up from 7,874 cases in 2021. This data underscores the significant impetus resulting from the growing prevalence of respiratory diseases, which propels the expansion of the respiratory inhaler devices market.

The rising smoking rates are expected to drive the growth of the respiratory inhaler devices market in the coming years. Smoking, which involves inhaling and exhaling the vapors of burning tobacco or other substances, can damage the airways and small air sacs (alveoli) in the lungs, leading to respiratory diseases such as asthma, COPD, and bronchitis. Respiratory inhaler devices are crucial for managing these conditions by alleviating symptoms and preventing further breathing difficulties. For instance, in September 2024, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported that tobacco use remains the leading cause of preventable disease and death in the United States. In 2022, about 49.2 million adults, or 19.8%, nearly 1 in 5, reported using tobacco products. As a result, the increasing smoking rates are driving the growth of the respiratory inhaler devices market.

Prominent companies within the respiratory inhaler devices market are increasingly adopting advanced technologies, such as metered dosage inhalers (MDIs), to fortify their market standing. MDIs represent portable aerosol devices designed to deliver precise medication doses to the lungs in the form of an inhaled mist or spray. For instance, a noteworthy development occurred in February 2022, when AptarGroup Inc., a US-based manufacturer specializing in consumer dispensing packaging and drug delivery devices, introduced HeroTracker Sense. This innovative digital respiratory health solution effectively transforms conventional metered dosage inhalers (pMDIs) into intelligent and connected medical devices. HeroTracker Sense aims to monitor the utilization of MDIs by patients, promoting better adherence to prescribed therapies and ultimately enhancing the lives of individuals worldwide grappling with chronic respiratory conditions like asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and respiratory complications triggered by COVID-19. HeroTracker Sense further offers invaluable analytics and insights related to patient training, onboarding, and performance, serving healthcare providers (HCPs) through the Aptar Pharma Cohero Health BreatheSmart Connect portal.

In August 2022, AptarGroup Inc., a US-based manufacturer specializing in consumer dispensing packaging and drug delivery devices, secured the global rights to the Orbital inhaler through an acquisition from Pharmaxis Ltd. This strategic acquisition of the Orbital inhaler rights aligns with Aptar Pharma's mission to expand its respiratory device portfolio and provide innovative solutions catering to patients grappling with respiratory conditions. Pharmaxis Ltd., an Australian-based pharmaceutical company with a clinical-stage focus, developed the groundbreaking Orbital dry powder inhaler. This strategic acquisition demonstrates a commitment to advancing respiratory care.

Major companies operating in the respiratory inhaler devices market are Merck & Co. Inc., Novartis AG, AstraZeneca PLC, Gerresheimer AG, GlaxoSmithKline PLC, 3M, Boehringer Ingelheim International GmbH, Koninklijke Philips N.V., Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., Perrigo Company PLC, AptarGroup Inc., Recipharm AB, Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Zydus Lifesciences Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Orion Corporation, Sumitomo Pharma America Inc., Beximco Pharmaceuticals Ltd., Hovione Limited, Vectura Group Limited, H&T Presspart Manufacturing Ltd., Pari Medical Holding GmbH, OMRON Healthcare Europe B.V., Medisol Lifescience Pvt. Ltd., Consort Medical plc.

North America was the largest region in the respiratory inhaler devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory inhaler devices report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the respiratory inhaler devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The respiratory inhaler devices market consists of revenues earned by entities by providing services such as the management of chronic lung diseases and minimizing systemic effects of the drugs. The market value includes the value of related goods sold by the service provider or included within the service offering. The respiratory inhaler devices market also includes sales of compressed air nebulizers, ultrasonic nebulizers and mesh nebulizers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Respiratory inhaler devices are compact, handheld tools designed to administer medication directly to the lungs. They are specifically engineered to deliver medications to the respiratory system, with a focus on the lungs, which helps minimize systemic drug effects and provides rapid relief during respiratory attacks or exacerbations.

The primary categories of respiratory inhaler device products include dry powder inhalers, metered dose inhalers, and nebulizers. Dry powder inhalers (DPIs) are medical devices that dispense powdered medications directly to the lungs for the treatment of respiratory conditions. These inhaler devices encompass both manually operated and digitally operated options. They are commonly used in the management of conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, and other respiratory issues. Respiratory inhaler devices find application in various healthcare settings, including hospitals, clinics, respiratory care centers, and other medical facilities. They serve as important tools for the delivery of respiratory medications and the management of respiratory conditions.

The respiratory inhaler devices market research report is one of a series of new reports that provides respiratory inhaler devices market statistics, including respiratory inhaler devices industry global market size, regional shares, competitors with a respiratory inhaler devices market share, detailed respiratory inhaler devices market segments, market trends and opportunities and any further data you may need to thrive in the respiratory inhaler devices industry. This respiratory inhaler devices market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.